GlassScriptPhysician profile
Jennifer Kinaga
NPI 1033504782
$3,724.89
in general payments reported to CMS, 2019-2025
33 companies · $1,034 in 2025
The $1,034 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $247 · 2020: $160 · 2021: $194 · 2022: $162 · 2023: $683 · 2024: $1,247 · 2025: $1,034.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,963.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,963.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shockwave Medical, INC | $441.70 | 2020-2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Kestra Medical Technology Services, INC. | $345.02 | 2024-2025 | Assure Wcd |
| Abbott Laboratories | $290.01 | 2019-2025 | Cardiomems |
| Amgen INC. | $280.39 | 2023-2025 | Repatha, Repatha |
| Astrazeneca Pharmaceuticals LP | $233.11 | 2024-2025 | Wainua, Farxiga |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $215.77 | 2021-2025 | Lifevest |
| Atricure, INC. | $197.87 | 2024-2025 | Atriclip Laa Exclusion System, Epi-Sense Guided Coagulation System With Visitrax |
| Pfizer INC. | $195.37 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $175.91 | 2023 | Xarelto |
| Novartis Pharmaceuticals Corporation | $175.45 | 2022-2025 | |
| Novo Nordisk INC | $154.00 | 2024-2025 | Wegovy, Ozempic |
| Penumbra, INC. | $153.42 | 2025 | Penumbra System |
| Merck Sharp & Dohme LLC | $102.52 | 2023-2025 | Verquvo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $102.43 | 2022-2025 | Jardiance |
| Medtronic Vascular, INC. | $100.00 | 2019 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $63.76 | 2023-2025 | Camzyos, Eliquis |
| Medtronic, INC. | $61.14 | 2023 | Hawkone |
| Baxter Healthcare | $48.89 | 2023-2025 | Hillrom - Cardiac Ambulatory Monitor, Hillrom - Carnation Ambulatory Monitor |
| Sanofi-Aventis U.S. LLC | $44.71 | 2023-2024 | |
| Kiniksa Pharmaceuticals International, Plc | $39.55 | 2024 | Arcalyst |
| Abiomed | $33.24 | 2021 | |
| Alnylam Pharmaceuticals INC. | $32.44 | 2025 | Amvuttra |
| Philips North America LLC | $29.94 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $28.30 | 2022 | |
| Bridgebio Pharma, INC. | $25.48 | 2025 | Attruby |
| Actelion Pharmaceuticals US, INC. | $22.88 | 2025 | Uptravi |
| Lexicon Pharmaceuticals, INC. | $21.48 | 2023 | Inpefa |
| Kiniksa Pharmaceuticals, LTD. | $21.06 | 2023 | Arcalyst |
| Heartflow, INC. | $19.75 | 2022 | |
| Cvrx, INC. | $19.09 | 2024 | Barostim Neo System |
| Astellas Pharma US INC | $18.82 | 2021 | |
| Genzyme Corporation | $16.42 | 2024 | |
| Lilly USA, LLC | $14.97 | 2025 | Mounjaro, Zepbound |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Kinaga listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.